More on REGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $607.93 |
|
|||
| Open | $612.07 | ||||
| 52 Wk High | $592.36 | ||||
| 52 Wk Low | $325.35 | ||||
| Day High | $616.24 | ||||
| Day Low | $598.19 | ||||
| P/E | 160.09 | ||||
| EPS | $3.81 | ||||
| Volume | 2,609,260 | ||||
- Form 8-K REGENERON PHARMACEUTICAL For: Jun 12
- Regeneron to present clinical data at medical conferences
- Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
- WHO recommends Regeneron antibody for Bundibugyo Ebola outbreak
- Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
- Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG
- Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASD
- Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
- Regeneron's Otarmeni gains EMA review for genetic hearing loss
- Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Entities mentioned with REGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
